Table 3. Univariate Analyses Assessing the Association of Time-Varying Exposures with Subsequent Hemorrhagic Cystitis.
Variable | Hazard Ratio (95% Confidence Interval) | P Value |
---|---|---|
Primary Exposures | ||
Peak BK plasma PCR* | ||
0 copies/mL | 0.9 (.3 to 2.5) | .83 |
1 to 9999 copies/ml | 5.3 (2.0 to 14.6) | <.01 |
10,000 to 99,999 copies/mL | No cystitis subject met this criterion | |
≥100,000 copies/mL | 34.3 (4.6 to 256.1) | <.01 |
Secondary Exposures | ||
Graft-versus-host disease | 1.0 (.2 to 4.9) | .99 |
Thrombotic microangiopathy | 2.2 (.7 to 6.9) | .18 |
Neutrophil engraftment | .6 (.1 to 2.7) | .49 |
Platelet engraftment > 20,000/μL | .4 (.1 to 1.3) | .12 |
Platelet engraftment > 50,000/μL | .3 (.1 to 1.4) | .14 |
Adenoviremia > 0 copies/mL | 1.3 (.4 to 4.7) | .70 |
CMV viremia > 0 copies/mL | 1.6 (.4 to 5.8) | .48 |
EBV viremia > 0 copies/mL | 2.1 (.6 to 7.8) | .26 |
HHV-6 viremia > 0 copies/mL | 7.6 (2.6 to 22.2) | <.01 |
CMV indicates cytomegalovirus; EBV, Epstein-Barr virus. Boldface indicates statistically significant.
Peak BK plasma PCR before cystitis in the hemorrhagic cystitis group and anytime during the first 100 days in the noncystitis group. For subjects with more than 1 identical peak value, the first date was used in the analysis.